Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MC4R | P32245 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6704676 | 0.72 | TP53 (0.46) | ALDH1A1LMNAHSD17B10CACNA1G | |
| SCHEMBL6325005 | 0.72 | MAPT (0.44) | ALDH1A1HTTLMNAHSD17B10MEN1 | |
| SCHEMBL6701422 | 0.71 | HPGD (0.46) | HPGDUSP2ALDH1A1MC4RHTT | |
| SCHEMBL6705567 | 0.70 | ALDH1A1 (0.47) | HPGDUSP2ALDH1A1MC4RHTT | |
| SCHEMBL29941835 | 0.68 | HPGD (0.66) | HPGDUSP2ALDH1A1MC4RHTT | |
| SCHEMBL8998862 | 0.68 | HPGD (0.66) | HPGDUSP2ALDH1A1MC4RHTT | |
| SCHEMBL16446872 | 0.68 | HPGD (0.57) | HPGDUSP2ALDH1A1MC4RHTT | |
| SCHEMBL16446870 | 0.68 | HPGD (0.57) | HPGDUSP2ALDH1A1MC4RHTT | |
| SCHEMBL2469546 | 0.67 | ALDH1A1 (0.86) | HPGDUSP2ALDH1A1MC4RTSHR | |
| SCHEMBL30239976 | 0.67 | MC4R (0.74) | HPGDUSP2ALDH1A1MC4RTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070123718-A1 | Novel 4-amino-2(5H)-furanones | ASTON UNIVERSITY (GB) | 2007-05-31 | — | — | US | disclosed |
| EP-1628966-A2 | 4-AMINO-2(5H)-FURANONES USEFUL AS CHOLECYSTOKININ ANTAGONISTS | Aston University (GB) | 2006-03-01 | — | — | EP | disclosed |
| WO-2004106315-A2 | 4-AMINO-2(5H)-FURANONES USEFUL AS CHOLECYSTOKININ ANTAGONISTS | ASTON UNIVERSITY (GB) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123718-A1 | Novel 4-amino-2(5H)-furanones | CBR1, CBR3, GPR18 | HPGD 1270/4885USP2 3846/4885ALDH1A1 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.